Scholarlink

Background <p>Metabolic dysfunction-associated steatohepatitis (MASH) increases risk of liver-related outcomes, yet comorbidities and mortality patterns remain unclear.</p> Methods <p>Using Optum Market Clarity, we identified adults with MASH and assessed associations of comorbidities and noninvasive tests with liver outcomes and mortality via Fine-Gray models.</p> Results <p>18,710 patients were identified (73.5% without cirrhosis, 9.0% with compensated cirrhosis (CC), 17.8% with decompensated cirrhosis, DC). The mortality rate was 0.82, 3.50, and 11.28 per 100 person-years (PY) for the non-cirrhosis, CC and DC subgroups, respectively. Among those without cirrhosis, progression to cirrhosis occurred at a rate of 5.71 per 100 PY. A FIB-4 score &gt; 2.67 vs. ≤ 2.67 was associated with a seven-fold increase in mortality risk (adjusted hazard ratio [aHR] = 7.06; 95% confidence interval [CI] = 6.37–7.83). Elevated AST levels (&gt; 40 U/L vs. ≤40 U/L; aHR = 1.38, 95% CI = 1.24–1.53) and living with ≥ 3 comorbidities (vs. none; HR:1.93, 95% CI 1.47–2.54) were also associated with increased mortality.</p> Conclusion <p>Our findings highlight the impact of MASH on patients and show how accessible noninvasive tests can identify those at highest risk, empowering timely care at every stage.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Metabolic dysfunction-associated steatohepatitis in the real world: clinical burden, disease progression, and risk stratification with non-invasive tests

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月26日

查看全文
  • Claudio Sartini,
  • Ronald Herrera,
  • Faizan Mazhar,
  • Zuleika Aponte Torres,
  • Mireia Raluy,
  • Mark Yates,
  • Alia Yousif,
  • Ramy Younes,
  • Jörn M. Schattenberg

摘要

Background

Metabolic dysfunction-associated steatohepatitis (MASH) increases risk of liver-related outcomes, yet comorbidities and mortality patterns remain unclear.

Methods

Using Optum Market Clarity, we identified adults with MASH and assessed associations of comorbidities and noninvasive tests with liver outcomes and mortality via Fine-Gray models.

Results

18,710 patients were identified (73.5% without cirrhosis, 9.0% with compensated cirrhosis (CC), 17.8% with decompensated cirrhosis, DC). The mortality rate was 0.82, 3.50, and 11.28 per 100 person-years (PY) for the non-cirrhosis, CC and DC subgroups, respectively. Among those without cirrhosis, progression to cirrhosis occurred at a rate of 5.71 per 100 PY. A FIB-4 score > 2.67 vs. ≤ 2.67 was associated with a seven-fold increase in mortality risk (adjusted hazard ratio [aHR] = 7.06; 95% confidence interval [CI] = 6.37–7.83). Elevated AST levels (> 40 U/L vs. ≤40 U/L; aHR = 1.38, 95% CI = 1.24–1.53) and living with ≥ 3 comorbidities (vs. none; HR:1.93, 95% CI 1.47–2.54) were also associated with increased mortality.

Conclusion

Our findings highlight the impact of MASH on patients and show how accessible noninvasive tests can identify those at highest risk, empowering timely care at every stage.